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tion 40). Cost-effectiveness of ACE inhibitor (ACE-I)
treatment of LVSD was estimated from 12 published
studies. RESULTS: We investigated 257 cases with CVA,
PVD or TIA and 199 controls. The overall prevalence of
LVSD was 28% in the cases and 6% in the controls. Past
history of MI was associated with a high risk of LVSD in
both cases (48%) and controls (33%) (Relative Risk
1.53, 95% CI 0.87–2.71). However, 21% of cases with
no past history of MI had LVSD in comparison with 1%
of the controls (Relative Risk 17.51, 95% CI 4.29–
71.40). Measurement of BNP cost more than ECG screen-
ing, was less sensitive and specific and consequently not
as cost-effective. Echoing only those patients with history
of MI was the most cost-effective strategy in cases and
controls (cost per LVSD detected $786 and $1,203). The
cost per additional LVSD detected by ECG screening of
patients with no MI was $1,392 in cases vs $22,304 in
controls. The cost per additional LVSD detected by echo-
ing all subjects was $3,349 for cases vs $40,488 for con-
trols. Screening and treating LVSD with ACE-I was cost-
effective ($50,000 per Life Year Saved) for all case
patients or for controls with a history of MI, but not for
controls with no history of MI ($134,963–$312,623 per
LYS). CONCLUSIONS: Screening patients with non-car-
diac vascular disease for LVSD is almost as cost-effective
as screening patients with a past history of MI. Both
strategies compare favorably with other interventions for
cardiovascular disease.
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OBJECTIVES: In acute sub-massive pulmonary embo-
lism (PE), Low Molecular Weight Heparins (LMWH) are
as effective as IV unfractionated heparin (UFH), but eas-
ier to administer with a slightly better adverse events pro-
file. In order to assess the health economic consequences
of LMWH, we examined the cost of using the LMWH
tinzaparin instead of UFH in the treatment of acute sub-
massive PE in Belgium, from a hospital perspective.
METHODS: The evaluation is based on a clinical trial
involving 612 patients (Simonneau et al, NEJM, 97), re-
porting differences in the adverse outcomes of both treat-
ments. In order to represent actual clinical practice in
Belgium, a 2-round Delphi-panel was conducted in which
clinicians produced data about average treatment pat-
terns. A patient record review looking at actual clinical
treatment of 54 patients with PE in five Belgian hospitals
was used to validate the findings from the panel. Initial
treatment costs that differed between the two strategies
and costs of adverse outcomes reported in the trial were
considered, since other costs (e.g. diagnosis) are the same
for both options. Drug costs were obtained from list
prices, and staff costs and material costs were provided
by University Hospital Gent. RESULTS: Even though
treating PE with tinzaparin increases drug costs, the total
cost of treating a patient is less than treatment with UFH:
Bef 4,817 (119.4 Euro) for UFH vs. Bef 3,837 (95.1
Euro) for tinzaparin. Tinzaparin removes the need for
aPTT tests, and produces savings on staff time, material
usage, and treating adverse events. The results are robust
both to the plausible range of uncertainty in the results of
the clinical trial and to broad changes in the medical re-
source use data. CONCLUSIONS: Overall, tinzaparin re-
duces costs through greater ease of administration, sav-
ing staff time and material costs, and by removing the
need for laboratory monitoring.
CV6
A MULTICENTER STUDY OF PHARMACIST 
DIRECTED INTERVENTIONS IN DYSLIPIDEMIA 
THERAPY
Reeg-Dhingra MP1, Howard PA1, Fincham JE2
1University of Kansas Medical Center, Kansas City, KS, USA; 
2University of Kansas School of Pharmacy, Lawrence, KS, USA
Dyslipidemia is an established risk factor for coronary
heart disease (CHD). Primary and secondary prevention
of dyslipidemia decreases CHD morbidity and mortality.
Compliance and persistence with HMG CoA reductase
inhibitor (“statin”) therapy has been sporadic, despite
the lipid lowering ability of these drugs. OBJECTIVES:
The purpose of this study was to determine if a struc-
tured, educational, pharmacist-directed intervention pro-
gram would influence the outcomes of dyslipidemia therapy.
METHODS: This study utilized a stratified, randomized,
open-label, fifty site multi-center comparison of a com-
munity pharmacy-based health education and medication
management program for dyslipidemia patients. Experi-
mental group patients received a structured, pharmacist
directed series of interventions and monthly lipid panel
measurements. Control patients received the traditional
standard of pharmacy care. Statistical analyses included
t-test examination of differences in mean values for lipid
panel measurements between groups. RESULTS: A ma-
jority of patients at baseline had CHD (57%) and 32%
of patients had 2 risk factors as indicated by National
Cholesterol Education Panel (NCEP) guidelines. Baseline
mean low-density lipoprotein (LDL) levels in the inter-
vention group and non-intervention group were 142 mg/
dl and 140 mg/dl respectively, indicating a majority of
moderate to high-risk patients was not at NCEP goal.
Findings to date do show improvements in total choles-
terol and LDL reduction after the pharmacist interven-
tion as compared to the non-intervention group, P 
0.001. Additionally, intervention patients reported im-
provements in the medication persistence survey scores.
